These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7726659)

  • 1. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
    Meisel M; Straube W; Weise J; Burkhardt B
    Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
    Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
    Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
    Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays.
    Ward BG; McGuckin MA; Ramm LE; Coglan M; Sanderson B; Tripcony L; Free KE
    Cancer; 1993 Jan; 71(2):430-8. PubMed ID: 8422635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
    McGuckin MA; Layton GT; Bailey MJ; Hurst T; Khoo SK; Ward BG
    Gynecol Oncol; 1990 May; 37(2):165-71. PubMed ID: 1693126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
    Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
    Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum CA 125 and ferritin in patients with ovarian carcinoma].
    Kanajet D; Klarić P; Filjak K
    Jugosl Ginekol Perinatol; 1988; 28(5-6):125-8. PubMed ID: 3216687
    [No Abstract]   [Full Text] [Related]  

  • 9. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
    Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
    J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is CA-125 monitoring useful in patients with epithelial ovarian carcinoma and preoperative negative CA-125 serum levels?
    Sevelda P; Rosen A; Denison U; Barrada M; Spona J; Salzer H
    Gynecol Oncol; 1991 Nov; 43(2):154-8. PubMed ID: 1743558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
    Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
    Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
    Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
    Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
    Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
    Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
    Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are CASA and CA125 concentrations in peripheral blood sourced from peritoneal fluid in women with pelvic masses?
    Ward BG; McGuckin MA
    Cancer; 1994 Mar; 73(6):1699-703. PubMed ID: 8156497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma].
    Kokocińska D; Worwag J; Tomala J; Dzieciuchowicz L; Nowak S; Kuśmierski S
    Ginekol Pol; 1994 Sep; 65(9):495-501. PubMed ID: 7721162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).
    Gronlund B; Høgdall EV; Christensen IJ; Johansen JS; Nørgaard-Pedersen B; Engelholm SA; Høgdall C
    Int J Biol Markers; 2006; 21(3):141-8. PubMed ID: 17013795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of determination of CA-125 in monitoring patients with ovarian carcinoma.
    Kamińska JA; Kowalska MM; Sablińska B; Pietrzak P
    Eur J Gynaecol Oncol; 1993; 14 Suppl():128-32. PubMed ID: 8200363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
    Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
    J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum copper in ovarian carcinoma.
    Jacobs AJ; Sommers GM; Axelrod JH; Galakatos AE; Kao MS; Camel HM
    Cancer; 1988 Mar; 61(5):1015-7. PubMed ID: 3422179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.